Here are four points:
1. The stock is down 2.54 percent from 4.29 million shares.
2. AmSurg has declined 7.84 percent since July 9, 2015..
3. The company has a market cap of $3.83 billion.
4. Of the 13 analysts covering the stock, 11 rate it “buy,” one rates it “sell” and another one analyst rates it “hold.”
More articles on ASC issues:
10 key thoughts on private practice profitability
5 statistics on accountable care organizations — 500 & counting
6 statistics on ophthalmologist income, assets & life goals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
